These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 2494697)

  • 1. ["Initial experiences with thrombolysis at Swiss hospitals" by H.P. Krayenbühl, H. Ziegler, T. Moccetti and R. Ritz, Schweiz. med. Wschr. 1988; 118: 1695-1697].
    Behrens M; Odavic R
    Schweiz Med Wochenschr; 1989 Feb; 119(6):196. PubMed ID: 2494697
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
    Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
    Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary thrombolysis with tissue-type plasminogen activator.
    Bergmann SR; Ludbrook PA; Sobel BE
    Cardiol Clin; 1987 Feb; 5(1):101-11. PubMed ID: 3103916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic thrombolysis: tissue-type plasminogen activator.
    Sobel BE
    Circulation; 1987 Aug; 76(2 Pt 2):II39-43. PubMed ID: 3111746
    [No Abstract]   [Full Text] [Related]  

  • 7. Coronary thrombolysis with tissue-type plasminogen activator: an overview.
    Van de Werf F; Collen D
    Eur Heart J; 1985 Nov; 6(11):902-4. PubMed ID: 3935445
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator.
    Braunwald E
    J Am Coll Cardiol; 1989 Nov; 14(6):1570-1. PubMed ID: 2509532
    [No Abstract]   [Full Text] [Related]  

  • 9. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
    J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group.
    Braithwaite BD; Buckenham TM; Galland RB; Heather BP; Earnshaw JJ
    Br J Surg; 1997 May; 84(5):646-50. PubMed ID: 9171752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distant haemorrhagic effects in intra-arterial tissue plasminogen activator--the effect of a bolus dose.
    Cripps NP; Ward AS
    J R Nav Med Serv; 1994; 80(2):66-70. PubMed ID: 7707276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New methods of thrombolysis].
    Vinazzer H
    Wien Med Wochenschr; 1987 Jun; 137(10-11):221-4. PubMed ID: 2955574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term benefit of one thrombolytic over another.
    Grobman BJ
    Circulation; 1997 Sep; 96(6):2093. PubMed ID: 9323115
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GUSTO: is science or money talking?
    Jackson G
    Br J Clin Pract; 1993; 47(4):175. PubMed ID: 8260330
    [No Abstract]   [Full Text] [Related]  

  • 17. [Canadian Consensus Conference on Coronary Thrombolysis--current aspects].
    Cairns J; Armstrong P; Belenkie I; Hirsh J; Johnstone D; Knudtson M; Lemieux M; Massel D; Naylor D; Roy L
    Can J Cardiol; 1995; 11(7):581-6. PubMed ID: 7656193
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical pharmacology of coronary thrombolysis.
    Tiefenbrunn AI; Robison AK; Sobel BE
    Cardiol Clin; 1987 Feb; 5(1):125-8. PubMed ID: 3103917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of MRI-based thrombolysis for patients with middle cerebral artery occlusionLi YH; Li MH; Zhao ZG; Bai QK
    Neurol India; 2009; 57(4):426-33. PubMed ID: 19770543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary thrombolysis.
    Thomas P; Sheridan DJ
    Q J Med; 1988 Sep; 68(257):657-63. PubMed ID: 2978484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.